ЕЭФФЕКТИВНОСТЬ ЛЕЧЕНИЯ И ИММУНОРЕЗИСТЕНТНОСТЬ В БОТУЛИНОТЕРАПИИ
- Авторы: Тимербаева С.1
-
Учреждения:
- НЦН РАМН
- Выпуск: Том 23, № 4 (2012)
- Страницы: 98-102
- Раздел: Статьи
- URL: https://journals.eco-vector.com/0236-3054/article/view/115506
- ID: 115506
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Ботулинотерапия - эффективный метод лечения заболеваний, сопровождающихся мышечными спазмами. В редких случаях возможны неудачи лечения. Иммунорезистентность - одна из причин вторичной неэффективности ботулинотерапии.
Ключевые слова
Полный текст
Список литературы
- Birklein F., Erbguth F. Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A - a preliminary observation // Mov. Disord. - 2000; 15 (1): 146-149.
- Brin M., Comella C., Jankovic J. et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay // Mov. Disord. - 2008; 23 (10): 1353-1360.
- Cordivari C., Misra V. P., Vincent A. et al. Secondary Nonresponsiveness to Botulinum Toxin A in Cervical Dystonia: The Role of Electromyogram-Guided Injections, Botulinum Toxin A Antibody Assay, and the Extensor Digitorum Brevis Test // Mov. Disord. - 2006; 21 (10): 1737-1741.
- Dressler D., Dimberger G. Botulinum Toxin Antibody Testing: Comparison between the Immunoprecipitation Assay and the Mouse Diaphragm Assay // Eur. Neurol. - 2001; 45 (4): 257-260.
- Dressler D., Bigalke H. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy // Mov. Disord. - 2002; 17 (1): 170-173.
- Dressler D., Münchau A., Bhatia K. et al. Antibody-Induced Botulinum Toxin Therapy Failure: Can It Be Overcome by Increased Botulinum Toxin Doses? // Eur. Neurol. - 2002; 47 (2): 118-121. 4'2012 ВРАЧ , 0
- Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy // Mov. Disord. - 2004; 19 (8): 92-100.
- Dressler D., Lange M., Bigalke H. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B // Mov. Disord. - 2005; 20 (12): 1617-1619.
- Dressler D., Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc // Eur. J. Neurol. - 2006; 13 (1): 11-15.
- Frevert J. Xeomin: an innovative new botulinum toxin type A // Eur. J. Neurol. -2009; 16 (2): 11-13.
- Frevert J., Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? // Biologics. - 2010; 9 (4): 325-332.
- Gelb D., Yoshimura D., Olney R. et al. Change in pattern of muscle activity following botulinum toxin injections for torticollis // Ann. Neurol. - 1991; 29; 370-376.
- Hanna P., Jankovic J., Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies // J. Neurol. Neurosurg. Psychiatry. - 1999; 66 (5): 612-616.
- Koman L., Brashear A., Rosenfeld S. et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial // Pediatrics. - 2001; 108 (5): 1062-1071.
- Lawrence I., Moy R. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A // Aesthet. Surg. J. - 2009; 29 (6): 66-71.
- Lee J., Yokota K., Arimitsu H. et al. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin // Microbiology. - 2005; 151 (11): 3739-3747.
- Moore P., Naumann M. General and clinical aspects of treatment with botulinum toxin. In: Moore P., Naumann M., editors. Handbook of botulinum toxin treatment, Second ed. Malden, Mass: Blackwell Science. - 2003: 28-75.
- Müller K., Mix E., Adib Saberi F. et al. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity // J. Neural. Transm. - 2009; 116 (5): 579-585.
- Naumann M., Carruthers A., Carruthers J. et al. Meta-analysis of neutralizing antibodyconversionwithonabotulinumtoxinA(BOTOX®)acrossmultipleindications//Mov. Disord. - 2010; 25 (13): 2211-2218.
Дополнительные файлы
